{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T17:08:03Z","timestamp":1784135283525,"version":"3.55.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.annder.2025.103446","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T20:38:06Z","timestamp":1764016686000},"page":"103446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Myasthenia gravis induced by encorafenib and binimetinib for metastatic melanoma"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8573-8609","authenticated-orcid":false,"given":"V.","family":"Groussin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Moumy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-2991","authenticated-orcid":false,"given":"C.","family":"Coltoiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Qu\u00e9reux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Piroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annder.2025.103446_b0005","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-023-12105-2","article-title":"Neurological toxicities of targeted therapies in melanoma: a multicenter national observational study of the French Group of Skin Cancers (Groupe de Canc\u00e9rologie Cutan\u00e9e, GCC)","volume":"271","author":"Hazard","year":"2024","journal-title":"J Neurol"},{"key":"10.1016\/j.annder.2025.103446_b0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annder.2025.103446_b0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1212\/WNL.0000000000008860","article-title":"Myasthenia gravis following dabrafenib and trametinib for metastatic melanoma","volume":"94","author":"Zaloum","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.annder.2025.103446_b0020","first-page":"11","article-title":"An unprecedented case of myasthenia gravis induced by binimetinib","volume":"9","author":"Alabdali","year":"2019","journal-title":"J Clin Case Rep"},{"key":"10.1016\/j.annder.2025.103446_b0025","first-page":"1405","article-title":"Neuromuscular complications following targeted therapy in cancer patients: beyond the immune checkpoint inhibitors. Case reports and review of the literature","volume":"42","author":"Demichelis","year":"2021","journal-title":"Neurol Sci off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"10.1016\/j.annder.2025.103446_b0030","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/bjh.15557","article-title":"Myasthenia gravis unmasked by imatinib","volume":"184","author":"Kopp","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annder.2025.103446_b0035","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.4081\/hr.2014.5288","article-title":"Development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib","volume":"6","author":"Sanford","year":"2014","journal-title":"Hematol Rep"},{"key":"10.1016\/j.annder.2025.103446_b0040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jns.2018.06.024","article-title":"New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent","volume":"392","author":"Desai","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.annder.2025.103446_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.727010","article-title":"Neuromuscular complications of targeted anticancer agents: can tyrosine kinase inhibitors induce myasthenia gravis? Getting answers from a case report up to a systematic review","volume":"11","author":"Ziogas","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.annder.2025.103446_b0050","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.0b013e3182074a69","article-title":"Neuromuscular junction toxicity with tandutinib induces a myasthenic-like syndrome","volume":"76","author":"Lehky","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.annder.2025.103446_b0055","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.36849\/JDD.7991","article-title":"Checkpoint inhibitor-induced neurotoxicity in a case of metastatic melanoma","volume":"22","author":"Burke","year":"2023","journal-title":"J Drugs Dermatol JDD"},{"key":"10.1016\/j.annder.2025.103446_b0060","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"}],"container-title":["Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382500105X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S015196382500105X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:44:34Z","timestamp":1784133874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S015196382500105X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S015196382500105X"],"URL":"https:\/\/doi.org\/10.1016\/j.annder.2025.103446","relation":{},"ISSN":["0151-9638"],"issn-type":[{"value":"0151-9638","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis induced by encorafenib and binimetinib for metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annder.2025.103446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103446"}}